`
`Paper No. _____
`Date Filed: March 9, 2016
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`MYLAN LABORATORIES LIMITED
`Petitioner,
`v.
`AVENTIS PHARMA S.A.
`Patent Owner.
`________________
`
`Case IPR2016-00627
`U.S. Patent No. 5,847,170
`________________
`
`
`
`AVENTIS PHARMA S.A.
`MANDATORY NOTICES – 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8, Aventis Pharma S.A. (the “Patent Owner”), as
`
`indicated by the assignment recorded at Reel/Frame 007959 / 0343, 011641 / 0962,
`
`and 011566 / 0692 submits the following Mandatory Notices.
`
`Real Party-In-Interest (37 C.F.R. § 42.8 (b)(1)):
`
`Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the real party-in-
`
`interest is Aventis Pharma S.A. (the “Patent Owner”). Sanofi, the ultimate parent
`
`company of Aventis Pharma S.A., and Sanofi-Aventis U.S. LLC, an affiliate of
`
`Aventis Pharma S.A. are also real parties-in-interest.
`
`Related Matters (37 C.F.R. § 42.8 (b)(2)):
`
`On January 14, 2015, Patent Owner, along with Sanofi-Aventis U.S. LLC
`
`and Sanofi (collectively “Sanofi”) filed a complaint averring that Petitioner’s
`
`Abbreviated New Drug Application (“ANDA”) No. 207381 concerning a proposed
`
`drug product, cabazitaxel injection [60 mg/1.5 mL] [40 mg/mL] infringes U.S.
`
`Patent No. 5,847,170 (“the ’170 patent”) under 35 U.S.C. § 271(e)(2). That
`
`lawsuit is pending in the United States District Court for the District of New Jersey
`
`and is captioned: Sanofi-Aventis U.S. LLC et al. v. Mylan Laboratories Limited,
`
`Civil Action No. 15-0290 (MAS)(LHG). Sanofi also filed additional complaints
`
`alleging infringement of the ’170 patent that are all pending in the United States
`
`District Court for the District of New Jersey and are captioned: Sanofi-Aventis U.S.
`
`LLC et al. v. Fresenius Kabi USA, LLC, C. A. Nos. 14-7869, 14-8082
`
`
`
`- 2 -
`
`
`
`
`
`
`(MAS)(LHG); Sanofi-Aventis U.S. LLC et al. v. Accord Healthcare, Inc., C. A. No.
`
`14-8079 (MAS)(LHG); Sanofi-Aventis U.S. LLC et al. v. BPI Labs, LLC et al., C.
`
`A. No. 14-8081 (MAS)(LHG); Sanofi-Aventis U.S. LLC et al. v. Apotex Corp. et
`
`al., C. A. No. 15-0287 (MAS)(LHG); Sanofi-Aventis U.S. LLC et al. v.
`
`Breckenridge Pharmaceutical, Inc., C. A. No. 15-0289 (MAS)(LHG); and Sanofi-
`
`Aventis U.S. LLC et al. v. Actavis LLC et al., C. A. No. 15-0776 (MAS)(LHG).
`
`Also, the following patent applications claim the benefit of the priority of the filing
`
`date of the subject patent: U.S. Patent Application Nos. 09/066,929 (now U.S.
`
`Patent No. 6,331,635), 09/752,779 (now U.S. Patent No. 6,372,780), and
`
`09/985,956 (now U.S. Patent No. 6,387,946).
`
`Designation of Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)):
`
`Lead counsel is Dominick A. Conde (Reg. No. 33,856). William E.
`
`Solander and Jason A. Leonard are designated as back-up counsel requiring pro
`
`hac vice admission to appear in this proceeding.
`
`A power of attorney from Aventis Pharma S.A. is being submitted with this
`
`- 3 -
`
`
`Notice.
`
`
`
`
`
`
`
`
`
`Service Information (37 C.F.R. § 42.8(b)(4)):
`
`Aventis Pharma S.A. may be served by postal mailing, hand-delivery,
`
`telephone or facsimile as follows:
`
`Dominick A. Conde
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`
`1290 Avenue of the Americas
`
`New York, NY 10104-3800
`
`Telephone:
`
`(212) 218-2100
`
`Facsimile:
`
`(212) 218-2200
`
`Aventis Pharma S.A. may be served electronically using the following e-
`
`mail addresses:
`
`
`
`
`
`
`
`dconde@fchs.com (lead counsel)
`
`wsolander@fchs.com (back-up counsel)
`
`jleonard@fchs.com (back-up counsel)
`
`
`
`- 4 -
`
`
`
`
`
`
`Any questions concerning this paper may be directed to lead counsel listed
`
`Respectfully submitted,
`
`
`
` /Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER & SCINTO
`Tel: (212) 218-2100
`
`Attorneys for Patent Owner,
`Aventis Pharma S.A.
`
`Back-up Counsel:
`William E. Solander (pro hac vice
`pending)
`Jason A. Leonard (pro hac vice
`pending)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`(212) 218-2100
`
`
`- 5 -
`
`
`below.
`
`March 9, 2016
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the Patent Owners’ Mandatory Notices Under 37
`
`C.F.R. § 42.8(a)(2) and Power of Attorney were served on March 9, 2016 by
`
`causing them to be sent by email to counsel for Petitioner at the following email
`
`addresses:
`
`sparmelee@wsgr.com
`
`mrosato@wsgr.com
`
`jmills@wsgr.com
`
`March 9, 2016
`
`Respectfully submitted,
`
`
`
` /Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel: (212) 218-2100
`
`
`- 6 -